CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

INTRODUCTION: Severe SARS-CoV-2 infection is associated with a dysregulated immune response. Inflammatory monocytes and macrophages are crucial, promoting injurious, proinflammatory sequelae. Immunomodulation is, therefore, an attractive therapeutic strategy and we sought to test licensed and novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Veenith, Tonny, Fisher, Benjamin A., Slade, Daniel, Rowe, Anna, Sharpe, Rowena, Thickett, David R., Whitehouse, Tony, Rowland, Matthew, Scriven, James, Parekh, Dhruv, Bowden, Sarah J., Savage, Joshua S., Richards, Duncan, Bion, Julian, Kearns, Pamela, Gates, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Intensive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587583/
https://www.ncbi.nlm.nih.gov/pubmed/34764169
http://dx.doi.org/10.1136/bmjopen-2021-050202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587583/
https://www.ncbi.nlm.nih.gov/pubmed/34764169
http://dx.doi.org/10.1136/bmjopen-2021-050202

Ejemplares similares